Stem Cell

India's First Stem Cell Therapy Laboratory Launched

It will introduce fat and skin cell therapies in near future

RMS Regrow, India's leading cell therapy services company, has launched its first cell therapy laboratory in Lonavala, in the state of Maharashtra. RMS lab will facilitate Cartilage regeneration therapy (Chondron) and bone regeneration therapy (Ossron). Chondron can enable prevention of early osteoarthritis and finally avoid total knee replacement. Strategically placed in Lonavala, the lab is easily accessible from Mumbai and Pune.

Based on the technology transfer from Sewon Cellontech, S Korea, the entire processing and quality control of the cell-based therapies has been designed and constructed in accordance with Good Manufacturing Practice (GMP)/Good Laboratory Practice (GLP) standards. The lab was inaugurated by the Guest of Honour, Dong Yern Kim, the Consul General of South Korea recently at the ceremony held at Shah Industrial estate, Nagargaon. Present at the occasion were Dr KH Sancheti, Founder, Sancheti Institute as Chief Guest, Dr Cheong-Ho-Chang, CEO & Chairman, Sewon Cellontech, South Korea as Chief Patron along with Satyen Sanghavi, Chief Scientific Officer, RMS Regrow.

A view of the lab in Lonavla

Said Dong Yern Kim, Consul General of South Korea, "India has emerged as a destination for innovative medical services and we are happy to have a technological collaboration between India and Korea." Outlining the progress and journey of RMS Regrow, Satyen Sanghavi, Chief Scientific Officer, RMS Regrow, said, "RMS lab is the only facility in India that provides cell culturing and application services for regeneration of cartilage and bone cells. With the launch of these therapies, patients can now get affordable treatment and easy access to medical assistance by reducing their overall cost by one fourth of what they would incur abroad. We wish to redefine the current treatments available in stem cell therapy and initiate the application of these therapies to hospitals and doctors for the fast and improved recovery for cartilage and bone repair. We will be soon introducing fat and skin cell therapies in near future."

Said Dr Cheong-Ho-Chang, CEO & Chairman, Sewon Cellontech, South Korea, "RMS Regrow is our partner and we wish to improve our technologies through their support and provide the best services in the field of regenerative medicine in India."

RMS Regrow will enable patients, particularly youngsters and sports personnel to resume their active life without being marred or setback by the defects in cartilage due to their strenuous activities. "Ossron will avoid endurance of complex, painful hip replacement surgeries which arise due to bone necrosis or other bone defects due to cancer and non-union fractures. Patients can look positively towards increasing the life longevity by more than 20 years," added Sanghavi.

EH News Bureau